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Abstract
Aims. To develop recommendations for strategies and interventions to reduce stigma and dis-
crimination related to coronavirus disease 2019 (COVID-19), through reviewing and synthe-
sising evidence in relation to COVID-19 and other disease outbreaks and infectious/
stigmatised conditions from systematic reviews and primary studies and recommendations
from additional materials.
Methods. Rapid review, drawing on the World Health Organization’s (WHO) methodology
for developing interim guidelines during health emergencies. PubMed/MEDLINE,
PsycINFO, Cochrane Central and Campbell Collaboration searched up to mid-April 2020.
Searches were supplemented by reference-searching and expert recommendations. Searches
were designed to identify: (1) systematic reviews (<10 years), or (2) primary intervention stud-
ies (no date limit) reporting evidence on anti-stigma interventions (in relation to COVID-19
or other infectious/stigmatised conditions) or (3) additional relevant materials. Data were
extracted on population, intervention, outcome and results. These data were compiled into
evidence summary tables and narrative overviews. Recommendations on strategies for
COVID-19 stigma-reduction were developed using the WHO ‘Evidence to Decision’ frame-
work approach. The review protocol was registered with PROSPERO (registration ID:
CRD42020177677).
Results. The searches identified a total of 4150 potentially relevant records, from which 12 sys-
tematic reviews and 29 additional articles were included. Overarching considerations and spe-
cific recommendations focus on: (1) language/words used in relation to COVID-19 and
affected people; (2) media/journalistic practices; (3) public health interventions; (4) targeted
public health interventions for key groups and (5) involving communities and key stakeholders.
Conclusions. These recommendations represent the first consolidated evidence-based guid-
ance on stigma and discrimination reduction in relation to COVID-19. Mitigating the impact
of stigma is critical in reducing distress and negative experiences, and strengthening commu-
nities’ resolve to work together during exceptional circumstances. Ultimately, reducing stigma
helps addressing structural inequalities that drive marginalisation and exacerbate both health
risks and the impact of stigma. Administrations and decision makers are urged to consider
integrating these recommendations into the ongoing COVID-19 response.
Introduction
A novel coronavirus pneumonia was first detected in Wuhan, China, in late 2019. This disease,
officially named coronavirus disease 2019, or COVID-19, is caused by the virus SARS-CoV-2
(severe acute respiratory syndrome coronavirus 2). The World Health Organization (WHO)
declared the disease outbreak a pandemic on 11 March 2020 (World Health Organization,
2020c). The emergence and rapid spread of this new viral diseases has caused confusion,
anxiety and fear among the general public. As with other public health emergencies and
perceived health threats, fear and anxiety about COVID-19 can result in stigma and discrim-
ination towards people associated with the disease (Centres for Disease Control and
Prevention, 2020).
Indeed, the COVID-19 pandemic has provoked stigmatisation and discriminatory beha-
viours against people who have, or might have, COVID-19 (World Health Organization,
2020b). The impact of stigma can be long-term, affecting the person beyond the acute
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phase of illness, continuing when people are no longer symptom-
atic, and when there is no longer a risk of others acquiring
COVID-19 from the person. Stigma can also occur by association,
meaning it affects people associated with COVID-19 through
their work (e.g. health and social care workers), affiliation with
a person who is unwell (e.g. caregivers, family members), and
people of certain ethnic backgrounds or country of origin (due
to public perception of places and populations amongst whom
the virus is more common or where it occurred earlier) (World
Health Organization, 2020b). These findings are in line with evi-
dence that stigma has been a key concern in relation to previous
comparable viral outbreaks and epidemics, for example severe
acute respiratory syndrome (SARS), Middle-East respiratory syn-
drome (MERS) and the Ebola virus disease (Person et al., 2004;
Fukuda et al., 2015; James et al., 2020).
Health-related stigma has been defined as a personal experience
or social process characterised by exclusion, rejection, blame and
devaluation, as a result of anticipating or experiencing negative
social judgements due to a person or group being in association
with a given health condition (Weiss and Ramakrishna, 2006).
Given the complex ways in which stigma can manifest, to facilitate
classification, stigma can been considered as composed of issues
related to inaccurate knowledge (e.g. regarding what an illness is,
how it is acquired), attitudes (e.g. stereotyped negative beliefs, or
negative emotional reactions) and behaviours (e.g. discriminatory
practices) (Thornicroft, 2006). Addressing stigma is important, as
it can drive people to deny or hide the illness to avoid discrimin-
ation, to prevent or delay timely health care seeking, and can dis-
courage people from adopting healthy behaviours (Stangl et al.,
2019). Such barriers could contribute to more severe health pro-
blems, and greater difficulties in controlling the viral disease out-
break (Van Bortel et al., 2016). Stigma and discrimination often
also affect the mental health of stigmatised people, which may itself
worsen these negative outcomes. Stigmatisation can also lead to
rejection, avoidance and social distancing of those who are feared
(Stangl et al., 2019), potentially leading to further harm, such as
making it harder for people to secure food or other basic necessities
(BBC News 2020).
Understanding and countering the COVID-19 stigmatisation
through interdisciplinary efforts has been highlighted as an urgent
priority (Holmes et al., 2020; IASC Inter-Agency Standing
Committee, 2020; Nature, 2020; World Health Organization,
2020a). In this context, the aim of this rapid review was to review
evidence at the onset of the pandemic to develop timely, relevant
and feasible recommendations for strategies and interventions to
reduce stigma and discrimination related to COVID-19.
Methods
Search strategy and selection criteria
This rapid review draws on the methodology of the World Health
Organization (WHO) ‘Health Emergency Interim Guidelines’
(Garritty et al., 2017; World Health Organization, 2017).
The review search strategy involves systematic database litera-
ture searches and expert consultations to identify relevant
resources to inform guideline recommendation development.
Inclusion criteria of relevant articles for inclusion were system-
atic reviews of any type of primary intervention studies (from the
past 10 years), any type of primary intervention studies (no date
limit) reporting on the efficacy of anti-stigma interventions (all
types of stigma) in relation to COVID-19 or in relation to the
following highly infectious/stigmatised conditions: SARS, MERS,
pandemic influenza, Ebola, tuberculosis, leprosy, HIV/AIDS or
mental illness.
The outcome of interest was changes in stigma (any type; e.g.
anticipated stigma, public stigma, self-stigma, structural stigma,
stigma-by-association, perceived stigma), or changes in outcomes
considered to be reflective of stigma (knowledge, attitudes,
behaviours).
The target populations were: people experiencing stigma (e.g.
people who are confirmed or suspected to have the condition,
or who have recovered; people associated with the condition
due to their work [e.g. healthcare workers], country of origin or
ethnicity; or because of an affiliation with someone who is unwell
[e.g. caregivers, family members]); or people who can act on
stigma (e.g. general public, policy makers, people associated
with the condition, or who have experience of the illness).
Database searches were conducted in PubMed/MEDLINE,
PsycINFO, Cochrane Central and Campbell Collaboration,
searched up to mid-April 2020. Search strategies were developed
and ran separately in relation to each condition, and each data-
base. In brief, we used a combination of search terms related to
stigma (e.g. ‘stigma’, ‘discrimination’) AND the given condition
(e.g. ‘COVID-19’, ‘2019-nCoV’, ‘SARS-CoV-2’). The searches fol-
lowed a stepwise approach. First, the ‘stigma AND condition’
search was carried out with a limit to systematic reviews of any
type of primary intervention studies reporting on the efficacy of
anti-stigma interventions, published in the last 10 years. If this
search yielded systematic reviews relevant for inclusion, no fur-
ther searches were run. If no relevant systematic reviews were
identified, then a second search was carried out for the ‘stigma
AND condition’ with a limit to any type of intervention study
reporting on the efficacy of an anti-stigma intervention. If no rele-
vant studies were identified, a third search was carried out for
‘stigma AND condition’, with no limits. The search strategies
are available in the online Supplementary Materials. Database
searches were supplemented by reference searching for further lit-
erature for inclusion, and expert recommendations regarding
potentially relevant articles.
Systematic reviews and primary studies identified through the
first and second steps of the database search were considered as
evidence for this review. Articles identified through the third
step of the database search were considered as ‘additional materials’
relating to stigma-reduction and the condition. Within the add-
itional materials, this review also considered related guidelines
and recommendations from credible international and national
public health organisations and intra- and inter-governmental
organisations, sourced through expert recommendations.
The evidence and additional materials sourced through the
searches were reviewed for inclusion following the WHO rapid
advice guideline development principles (Garritty et al., 2017;
World Health Organization, 2017). A key systematic review article
(reflecting most recent, or most comprehensive evidence) was
selected to provide evidence on stigma-reduction in relation to
each condition (COVID-19, or other infectious/highly stigmatised
condition); within conditions also considering evidence regarding
type of stigma (e.g. self-stigma, public stigma, etc.), population
(e.g. person living with illness, general public) and setting (e.g.
healthcare), as relevant. Decisions regarding inclusion were
made through discussion between the two lead authors and
endorsed by the full review group (all authors).
The protocol for this review was registered on PROSPERO (ID:
CRD42020177677).
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Data synthesis
The lead authors (PCG, MN) individually extracted information
on population, intervention, outcome and results from the
included evidence articles, and subsequently reviewed each other’s
extraction for accuracy. Extracted data were compiled into evid-
ence summary tables, and reviewed for accuracy through group
discussions. Methodological quality of included evidence was
assessed using standard criteria in the AMSTAR-2 (Shea et al.,
2017) framework, to aid recommendation development.
Narrative overviews focused on information regarding stigma
reduction were also made for each included evidence article and
additional materials.
Following the WHO methodology for rapid development of
recommendations, data from the included evidence article and
additional materials were used to populate a GRADE Evidence
to Decision (EtD) framework (Alonso-Coello et al., 2016). Here
the review question (‘which interventions are effective in reducing
COVID-19 related stigma?’) is considered in relation to various
criteria (e.g. whether the problem addressed [COVID-19 stigma]
is considered a priority, whether there is variability in how the
outcome of interest [stigma] is valued, whether the favourable
effects of an intervention [stigma reduction] outweigh potential
undesirable effects; see online Supplementary Materials for fur-
ther details). The data within the EtD framework are used to sup-
port the development of evidence-informed health system and
public health recommendations and decisions, through a debate
considering the available evidence and insights from additional
materials as synthesised within the framework. Based on this dis-
cussion, the review group developed recommendations regarding
effective strategies for stigma reduction in relation to COVID-19.
Results
The searches identified a total of 4150 records, reflecting 2974
records of potentially relevant systematic reviews, 39 primary
studies and 1137 articles representing additional materials.
From these, 12 systematic reviews were selected as evidence for
this review, no primary studies met the criteria, and 29 articles
were included as additional materials. Figure 1 provides an over-
view of the article selection process.
The characteristics of the systematic reviews providing evid-
ence for this review are presented in Table 1 (added details in
online Supplementary Materials). These reviews reported on the
effectiveness of anti-stigma interventions in relation to leprosy
(Sermrittirong et al., 2014), tuberculosis (Sommerland et al.,
2017), HIV/AIDS (Andersson et al., 2019; Feyissa et al., 2019;
Ma et al., 2019; Pantelic et al., 2019) and mental illness
(Clement et al., 2013; Mehta et al., 2015; Hanisch et al., 2016;
Büchter and Messer, 2017; Heim et al., 2018; Mills et al., 2020).
In terms of stigma, most reviews focused on general stigma in
relation to the condition (Clement et al., 2013; Sermrittirong
et al., 2014; Mehta et al., 2015; Hanisch et al., 2016;
Sommerland et al., 2017; Heim et al., 2018; Feyissa et al., 2019;
Ma et al., 2019; Pantelic et al., 2019), but self-stigma (Büchter
and Messer, 2017; Mills et al., 2020), and enacted, anticipated
or internalised stigma (Andersson et al., 2019) were also consid-
ered. Some reviews focused on stigma in specific target groups or
settings; namely affected persons and their families (Büchter and
Messer, 2017; Andersson et al., 2019; Ma et al., 2019), healthcare
workers (Heim et al., 2018; Feyissa et al., 2019) or low- and
middle-income countries (Mehta et al., 2015; Heim et al., 2018;
Pantelic et al., 2019). No evidence (i.e., systematic reviews or pri-
mary intervention studies) was identified for stigma-reduction
directly in relation to COVID-19, SARS/MERS, influenza or
Ebola. Most reviews included evidence from studies using a
broad range of quantitative designs (generally this included
randomised-control trials or RCTs) (Clement et al., 2013;
Mehta et al., 2015; Hanisch et al., 2016; Feyissa et al., 2019; Ma
et al., 2019; Pantelic et al., 2019), one focused on RCTs specifically
(Büchter and Messer, 2017), and some included evidence from
quantitative, qualitative and/or mixed methods studies
(Sermrittirong et al., 2014; Sommerland et al., 2017; Heim
et al., 2018; Andersson et al., 2019; Mills et al., 2020).
The methodological quality of the included systematic reviews
was mixed (for results see online Supplementary Materials). The
most common limitations were a lack of registered review proto-
cols, providing no rationale for why the review focused on given
study designs, no references provided for excluded studies, no
reporting of funding information for included studies, and no
assessment of potential publication bias.
Additional evidence on stigma reduction was included in rela-
tion to COVID-19 (American Psychological Association, 2020;
Asmundson and Taylor, 2020; Centres for Disease Control and
Prevention, 2020; Devakumar et al., 2020; Earnshaw, 2020;
IASC Inter-Agency Standing Committee, 2020; Lin 2020; Logie
and Turan, 2020; Nature, 2020; World Health Organization,
2020a, 2020b), SARS (Person et al., 2004), influenza (Barrett
and Brown, 2008; Earnshaw and Quinn, 2013), Ebola (Davtyan
et al., 2014; IASC Reference Group on Mental Health and
Psychosocial Support, 2015; Mayrhuber et al., 2017), tuberculosis
(Chang and Cataldo, 2014), leprosy (Topp et al., 2019), HIV/
AIDS (Mak et al., 2017; Hartog et al., 2020), mental illness
(Thornicroft et al., 2016; Janoušková et al., 2017; Nyblade et al.,
2019) and mixed conditions (Mak et al., 2006, 2009; Fischer
et al., 2019; Rao et al., 2019; World Health Organization, 2019).
These additional materials represented a mixture of editorials,
commentaries, opinion pieces, correspondence and narrative
reports; technical guidance, or briefing papers/reports; data-based
studies reporting on stigma experiences; systematic reviews (that
were not selected as key evidence for this review, or that did
not meet criteria for inclusion as evidence); and one scoping
review. For further details see online Supplementary Materials.
Recommendations for principles and actions to reduce stigma
and discrimination related to COVID-19 were made based on
these data providing evidence and insights regarding effective
stigma-reduction in relation to highly infectious and stigmatised
conditions, and stigma during infectious disease outbreaks.
The recommendations are prefaced with the following over-
arching considerations:
• The link between stigma and COVID-19, and its impact, should
be considered for people who have a current confirmed
COVID-19 diagnosis, and also people who have been in
COVID-19 quarantine, received COVID-19 treatment, and peo-
ple associated with COVID-19 due to their work (e.g. health or
social care workers), ethnicity or country of origin (given public
perceptions of populations among whom the virus is considered
more common), or an affiliation with a person who is unwell or
otherwise associated with the virus (e.g. caregivers, family mem-
bers, peers).
• Interventions to reduce COVID-19 stigma are recommended
in all countries (high-, middle- and low-income) as stigma is
likely to manifest across cultures where effective
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interventions to reduce such stigma are likely to share simi-
lar basic characteristics (subject to local modifications/
adaptations).
• All intervention messages should be accessible to people of dif-
ferent ethnic and cultural groups, people with limited literacy,
and people who require accessible formats due to disability.
Inviting these groups to participate in planning and implemen-
tation of activities related to reducing COVID-19 stigma
improves the quality and effectiveness of such messaging.
• Politicisation of management of the pandemic must be avoided
as this may lead to further stigma and discrimination, and
reduce the effectiveness of other efforts to combat COVID-19.
Impacts of negatively singling out populations affected by the
pandemic is likely to endure after the current health crisis.
The recommendations are most effective if carried out together,
as part of a comprehensive response implemented within an
integrated approach to promote social inclusion and individual,
family and community recovery.
Specific recommendations on stigma reduction were developed
in relation to: (1) language and words used in relation to
COVID-19; (2) media and journalistic practices; (3) public health
interventions; (4) targeted interventions for key groups and (5)
involving communities and key stakeholders. These
Fig. 1. PRISMA flow diagram of the article selection process.
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Table 1. Characteristics of articles providing evidence for this review
Study
Stigmatised
condition Intervention focus (stigma target) Population Results
Andersson et al.
(2019)
HIV/AIDS HIV-related enacted, anticipated or
internalised stigma.
People with HIV n = 27 studies. Group-based behavioural
interventions, patient-centred mental
health programmes and community
support initiatives reduced stigma.
Büchter and
Messer (2017)
Mental illness Self-stigma People with mental
illness
n = 5 studies. No statistically significant
effect found. None of included study found




Mental illness Mental health-related stigma,
mass media interventions
General public n = 22 studies. Mass media interventions
may reduce prejudice in the immediate,




HIV/AIDS HIV-related stigma in healthcare
settings
Healthcare workers n = 14 records reporting on eight studies.
Training popular opinion leaders can
reduce avoidance intent and prejudicial
attitudes, and improve compliance to
universal precaution (moderate quality
evidence). Professionally assisted peer
group interventions, modular interactive
training, participatory self-guided
assessment and intervention, contact
strategy combined with information giving




Mental illness Mental illness-related stigma at
the workplace
People in the workplace n = 16 studies. Ten interventions increased
mental-health knowledge. Six studies (with
high risk of bias) improved mental-health
literacy. Nine studies improved attitudes.
All types of anti-stigma interventions in 11
studies consistently had a significant
positive impact on employees’ supportive




Mental illness Mental health-related stigma in
primary health care settings in
low- and middle-income countries
(LMICs)
Primary health care staff n = 18 studies. Most studies found positive
effects on attitudes of primary healthcare
staff towards people with mental illness,
but some effects were rather small.
Ma et al. (2019) HIV/AIDS HIV-related self-stigma People living with HIV/
AIDS and their families
n = 23 studies. Psycho-education, support
for treatment adherence, psychotherapy,
narrative interventions, and community
participation interventions show promising
trend of stigma reduction.
Mehta et al.
(2015)
Mental illness Question (1) Mental health-related
stigma, with long- and
medium-term follow-up
Question (2) Mental health-related
stigma in LMICs
Any Question 1 n = 72 studies; Question 2 n = 11
studies. Question (1) Modest evidence for
the effectiveness of anti-stigma
interventions beyond 4 weeks follow-up
(increasing knowledge, reducing
stigmatising attitudes).
Question (2) No statistically significant
improvements in knowledge. Significant
reductions in stigmatising attitudes. No




Mental illness Self-stigma, self-help interventions People with mental
illness
n = 8 studies. Self-help interventions can
reduce self-stigma, specifically depression




HIV/AIDS HIV-related self-stigma, in LMICs People living with HIV
and key populations
affected by HIV
n = 20 studies. Structural interventions
such as scale-up of antiretroviral
treatment, prevention of medication
stockouts, social empowerment and
economic strengthening may help reduce
self-stigma.
(Continued )
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recommendations are outlined in Box 1, and elaborated in the
online Supplementary Materials.
Discussion
This rapid review developed timely and feasible recommendations
for reducing stigma and discrimination in relation to COVID-19,
thus responding to calls for scientific advice and evidence-based
recommendations for stigma-reduction strategies in this public
health emergency (Nature, 2020). Our recommendations specify
overarching considerations that should underpin any efforts to
reduce COVID-19-related stigma, from the outset of the pan-
demic and beyond, as well as providing strategies and actions to
take at the micro-, meso- and macro levels to reduce stigma
and discrimination.
Our recommendations represent the first consolidated set of
guidance on principles for reducing stigma and discrimination in
relation to COVID-19, responding to recent calls for scientific
advice and evidence-based recommendations for stigma-reduction
strategies in relation to COVID-19. Given the negative impact
stigma and discrimination on people’s physical and mental health
and wellbeing, social equity, livelihoods and on efforts to control
the disease outbreak (Stangl et al., 2019; Devakumar et al., 2020;
World Health Organization, 2020b), these recommended
stigma-reduction strategies are of critical importance within the
wider context of responses to the pandemic.
These recommendations are anticipated to be actionable by
policy makers, public health officials, planners and managers at
the local and national levels, researchers, media representatives,
national and international non-governmental organisations,
community-based organisations, people affected by COVID-19
(directly or by association), and lay people.
The strength of this review and the resulting recommendations
for principles of stigma-reduction related to COVID-19 lies in
the transparent and robust methodologies that were applied for
sourcing evidence and other materials for inclusion and data syn-
thesis, the multidisciplinary sources of evidence, and the develop-
ment of recommendations following a transparent and rigorous
WHO methodology.
These recommendations do, however, need to be considered in
view of some limitations. Given the urgency, a rapid review
approach was taken for the systematic searches, and an expedited
procedure utilised for the process to develop the recommenda-
tions, as per WHO guidance. Although rapid reviews methodolo-
gies in response to developing emergencies have limitations
(Clarke, 2020), it is a recommended approach for feasible and
timely evidence gathering and synthesis, and for the development
of expedited recommendations for action. Rapid reviews are
intended to provide initial guidance in emergencies, but we
believe our work will also make a contribution beyond the imme-
diate ongoing emergency given the long-term perspective of the
recommendations, and the robust methodology underpinning
the review. We envision that these recommendations provide a
starting point for further, more comprehensive stigma reduction
recommendations in relation to COVID-19. For now, implement-
ing a full WHO guideline development procedure would have
been excessively time consuming (these processes typically take
1–2 years), which is unfeasible under circumstances where
stigma-reduction in relation to COVID-19 is highlighted as a pri-
ority. It also needs to be noted that these recommendations are
based on a mixture of evidence from systematic reviews and
insights from additional materials. Although the use of evidence
plus additional considerations is part of the GRADE approach,
we acknowledge that our recommendations are based on a limited
evidence base. Thus, to make the most of all available in-
formation, an a-priori decision was made to consider evidence
from systematic reviews and primary intervention studies, as
well as insights from the additional materials to inform recom-
mendations. The additional materials could not be assessed for
methodological quality, given how no rating tool is available
that would allow for useful comparisons between the range of
materials that were included. To allow for recommendations to
be assessed in view of this, we have indicated whether each recom-
mendation is based on systematic review evidence or additional
materials. Given the recency of the COVID-19 pandemic, no
direct evidence on effective stigma reduction in relation to
COVID-19 was available to inform the recommendations. We
had accounted for this possibility by planning to extrapolate evi-
dence on effective stigma-reduction also from other disease out-
breaks and infectious/stigmatised conditions. This means the
recommendations are based on the assumption of generalisability
between the conditions. However, this approach is in line with
recommendations to consider health-related stigma across condi-
tions, rather than separately for each condition in a siloed man-
ner, to facilitate public health responses and the ability to act
on stigma (Stangl et al., 2019; Van Brakel et al., 2019). Using learn-
ings on stigma-reduction strategies from previous disease outbreaks
and infectious/stigmatised conditions to inform strategies in relation
to COVID-19 is, in our view, the best available approach to formu-
late informed recommendations where direct evidence is not avail-
able, and is an approach that has been utilised previously (Mak




condition Intervention focus (stigma target) Population Results
Sermrittirong
et al. (2014)
Leprosy Leprosy-related stigma General public, medical
staff, patients with
leprosy
n = 25 studies. Interventions with evidence
of effective stigma reduction: integration of
leprosy programmes into general health









n = 7 studies. Knowledge-shaping and
attitude-changing interventions reduced
anticipated stigma. Home visits and
support groups reduced both anticipated
and internalised stigma.
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Box 1. Recommendations for reducing stigma and discrimination related to COVID-19
1. Language and words†
1.1 Language and words reflecting stigmatising attitudes should not be used when talking about COVID-19. It is recommended: not to attach locations or
ethnicity to the disease, not to refer to people with COVID-19 as ‘cases’, ‘victims’ or ‘suspects’; not to use exaggerated language or metaphors (e.g.
‘plague’).
1.2 Over-emphasising attribution of disease burden, severity and death to ethnicity, pre-illness behaviour/travel history, age, gender or underlying medical
conditions should be avoided as it devalues affected people, assigns blame, can lead to a false sense of security in the rest of the population, and
undermine epidemic control measures.
1. Media and Journalists†
2.1 Language in the media should be considered both as a delivery platform for anti-stigma strategies and as a target for anti-stigma efforts, as media
reporting can shape popular perceptions, discourse, communication and behaviour.
2.2 Mass media should be employed to share balanced and accurate information, focused on avoiding COVID-19 stigma. Sensationalist headlines/stories
should be avoided. Journalists have an ethical responsibility to convey messages based on good science and disease management principles.
2.3 Communication training should be provided for those in government and in health/care services, including those providing public briefings.
2.4 People affected by COVID-19 should be involved in shaping media language.
1. Public health interventions
3.1 COVID-19 stigma-reduction strategies targeting the general public should build on knowledge-shaping and attitude-changing strategies.*
3.2 Stigma among the general public can be reduced by providing treatment programmes for stigmatised conditions within general health care settings; this
consideration is particularly relevant in the treatment of possible long-term complications following COVID-19*
3.3 Mass media interventions targeting the general public are recommended to reduce prejudice in the immediate, short and medium term.*
3.4 Anti-stigma campaigns should include correcting myths, rumours and stereotypes, and challenging bias. Emphasis should go beyond factual knowledge,
to strategically addressing specific public misconceptions, which may vary among different populations and cultural/religious groups.†
3.5 Using artists and art to showcase stories, conditions and experiences of people who have suffered discrimination can cultivate engagement, empathy,
acceptance and social change.†
3.6 Messaging should emphasise the joint social responsibility to support efforts to reduce impacts of COVID-19. Focus on a sense of community and jointly
achieved positive outcomes is more likely to succeed than actions directed by fear or shaming. Messaging should include publicly supporting frontline
workers, those who volunteer/assist vulnerable populations, and people from these communities (often disproportionately represented among frontline
workers).†
3.7 Strategies to reduce and/or slow down transmission through avoiding physical contact should be framed as ‘physical distancing’, rather than ‘social
distancing’ or ‘social isolation’. Remaining socially connected, and promoting a sense of community, support, common purpose and inclusion is likely to
improve solidarity.†
3.8 Universal public health strategies (e.g. testing; stimulus checks; policies like physical distancing, travel bans and quarantine) can reduce stigma (vs.
targeted strategies, which can imply blame on particular individuals/groups).†
3.9 Excessive policing or criminalising the breaching of COVID-19-related health policies is likely to increase stigma and discrimination, and risks loss of trust
which may in turn reduce compliance with such measures or lead to protests.†
3.10 Comprehensive stigma mitigation requires public health strategies implemented in the immediate term (e.g. addressing misinformation) complemented
by efforts to tackle societal-level issues of social and economic inequalities that facilitate stigma in the long term (e.g. racism, xenophobia, structural-level
policies and laws).†
1. Targeted public health interventions for key groups
People directly affected by COVID-19
4.1 Stigma (anticipated, enacted, internalised) can be reduced through strategies building on group-based interventions, psycho-educational interventions,
social empowerment strategies, community-based strategies and self-help interventions.*
Family members
4.2 Interventions should build on positive, community-proposed coping strategies. Family-based interventions and strategies based on empowerment are
recommended to mitigate self-stigma.†
Health care and frontline workers
4.3 Health care professionals and key frontline workers need protection from discrimination and abuse, as this will increase stress and work-pressures,
affecting their ability to work. Interventions to support and provide encouragement/counselling for those on COVID-19 frontlines are strongly recommended.*
4.4 An information-based approach, including the involvement of popular opinion leaders, should be implemented to reduce stigma against health workers.*
Vulnerable/high-risk populations
4.5 Tailored anti-stigma interventions and protection should be ensured for disadvantaged and marginalised groups (e.g. homeless people, people with
disabilities, people who are incarcerated, migrants and refugees, and racial minorities), who may be particularly exposed to stigma and exclusion and at
increased risk of COVID-19.†
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Future research should continue to assess the nature of stigma
in relation to COVID-19, and the implementation and impact of
the recommended stigma-reduction strategies, including, for
example, qualitative operational research in humanitarian set-
tings, the scalability and sustainability of anti-stigma interven-
tions, and the cost-effectiveness of such interventions. The
evidence should be used to revise and refine the recommenda-
tions regarding best practice to reduce stigma in relation to
COVID-19 and other infectious disease epidemics. Studies are
also needed to examine commonalities and differences in stigma
and discrimination in differences in cultures and settings.
Comparing the effectiveness of interventions in different popula-
tions will help confirm the extent to which interventions are gen-
eralisable across settings. People who have direct experience of
COVID-19 associated stigma should play a key role in the devel-
opment and implementation of such research. Research efforts
should attempt to avoid the common limitations of stigma
research, such as small-scale studies, heterogeneous designs,
mixed methodological quality, lack of contextually and culturally
adapted interventions, unvalidated outcome measures, limited
evaluation of long-term impacts of interventions and behavioural
outcomes, and limited evidence from low- and middle-income
settings. Methodologically sound research generates stronger evi-
dence, and increased harmonisation across studies would allow
for the results to be pooled using robust synthesis methods for
increased impact.
In conclusion, the recommendations developed through this
rapid review at the onset of the pandemic provide strategies for
the reduction of stigma and discrimination associated with
COVID-19 at the micro-, meso- and macro level. They are a
necessary complement to wider public health measures, both at
the onset of a pandemic and beyond, and we urge administrations
and decision-makers to recognise these recommendations and
how these practices can be integrated into the ongoing
COVID-19 public health, social and humanitarian sectors
response, and subsequent long-term plans, to counter the stigma
and discrimination evident in relation to the pandemic at all
stages of an outbreak, including societies’ recovery from it.
Mitigating the impact of stigma is of critical importance, not
only to reduce distress and negative experiences for people who
are discriminated against, but also to strengthen communities’
resolve to work together during exceptional circumstances, and
facilitate adherence to public health strategies and health
behaviours that help to control a viral disease outbreak.
Stigma-reduction strategies will not only reduce distress and nega-
tive experiences in the immediate term, but critically a commit-
ment to the reduction of stigma and discrimination will
ultimately address deeper patterns of structural inequalities that
drive stigma, social and economic marginalisation, and exacerbate
both health risks and the impacts of stigma, in relation to
COVID-19 and health conditions overall. Social inclusion, justice
and solidarity are key components of health protection, required
in the immediate term to manage the current COVID-19 public
health emergency, but also in the long term for communities
and countries to recover from its impact, and to be better pre-
pared to respond to further waves of the outbreak or to compar-
able pandemics in the future.
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